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Abstract
BACKGROUND: Acteoside is a phenylethanoid compound isolated from Jacaranda mimosifolia D. Don leaves with 
a potential antidiabetic effect.
OBJECTIVES: This study was designed to investigate the antidiabetic and antioxidant effects of acteoside in 
streptozotocin-nicotinamide (STZ-NA)-induced Type 2 diabetes in rats.
METHODS: Diabetes was induced by intraperitoneal (i.p.) injection of a single dose of STZ (52.5 mg/kg), 15 min 
following i.p. administration of NA (25 mg/kg). Rats were divided into six groups; Group I: Normal rat group received 
the vehicle, Group II: Diabetic control group, and Groups III-IV: Diabetic rat groups were treated by either oral 
acteoside (10, 20, and 40 mg/kg) or pioglitazone (30 mg/kg) for 21 consecutive days. Biochemical parameters were 
assessed in the serum and liver homogenates. Examination of liver sections for histopathology was also carried out.
RESULTS: Acteoside treated rats showed significant lower levels of blood glucose, glycosylated hemoglobin, total 
cholesterol, triglycerides, and increased serum insulin compared to control diabetic rats. Furthermore, acteoside 
treated rats, in comparison to the diabetic control, demonstrated significantly reduced malondialdehyde, increased 
reduced glutathione liver contents, and attenuated pathological alterations in the liver. These effects were comparable 
to those caused by the standard antidiabetic drug, pioglitazone. In vitro, acteoside scavenged stable free radical 
1,1-diphenyl-2-picrylhydrazyl.
CONCLUSION: Acteoside could be considered as a potential therapeutic agent for type 2 diabetes mellitus. 
However, studying further mechanisms underlying its antidiabetic effect is recommended.
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Introduction
Diabetes mellitus is a chronic metabolic 
disorder affecting about 450 million adults around 
the world. The number is expected to reach 629 
million by 2045 [1]. The disease is characterized by 
hyperglycemia induced by diminished insulin output 
from pancreatic beta cells and/or tissues’ resistance 
to insulin action. Type 2 diabetes is found in 90–95% 
of all diabetes cases. Diabetes is associated with high 
risk of macrovascular and microvascular (nephropathy, 
neuropathy, and retinopathy) complications [2]. Lifestyle 
modifications, pharmacological treatments and careful 
monitoring are the mainstay for diabetes management. 
Achieving target glycemic control helps preventing or at 
least can delay diabetes complications [3].
Despite the benefits of current antidiabetic 
drugs, every class has undesirable adverse effects. 
Therefore, searching for new treatments for type 2 
diabetes is warranted. New drugs should be efficacious 
with minimal adverse effects and affordable cost. 
Diabetic patients use natural remedies that are thought 
to improve glycemic control especially in areas where 
the cost of drugs imposes a real challenge [4]. The 
genus Jacaranda (Bignoniaceae) is found mainly in 
tropical and subtropical geographical areas. Jacaranda 
mimosifolia is native to Brazil but is also cultivated as an 
ornamental tree in Egypt. Acteoside (verbascoside) was 
isolated from the leaves of the J. mimosifolia [5]. A variety 
of promising activities of acteoside was reported in the 
previous studies including anti-inflammatory [6], [7], 
hepatoprotective [8], antioxidant [9], antineoplastic [10], 
and neuroprotective effects [11].
Previous reports have demonstrated the 
potential anti-hyperglycemic effect of acteoside. 
For example, acteoside prevented protein glycation 
in vitro, an activity that is correlated with antidiabetic 
drugs [12]. Moreover, plant extracts containing acteoside 
showed anti-hyperglycemic effects in experimental type 
2 diabetes [13]. Furthermore, a more direct testing of 
the potential hypoglycemic action of acteoside was 
reported in the study by Morikawa et al. [14]; after 2 
weeks of daily oral acteoside given concurrently with 
a starch load in mice, glucose tolerance was improved 
without significant change in weight. However, the 
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antidiabetic effect of acteoside has not been yet explored 
in experimental diabetes models. Therefore, this work 
aims to investigate the antidiabetic and antioxidant 
effects of acteoside in a rat model of Type 2 diabetes 
induced by streptozotocin-nicotinamide (STZ-NA).
Materials and Methods
Animals
Male Wistar albino rats (weight 180–210 g) were 
used in the current study. Rats were purchased from the 
Animal House Facility of the National Research Centre 
(Cairo, Egypt). Animals were housed in standardized 
conditions and allowed to acclimatize for 7 days in the 
laboratory before starting the experiment. Rats had free 
access to a standard food pellets and water ad libitum. 
The experimental protocol and all animal procedures 
were approved by the Ethics Committee of the National 
Research Centre, Egypt (approval number: 18/042). 
The committee guidelines are in line with the National 
Institutes of Health guide for the care and use of 
laboratory animals.
Materials
STZ was procured from Sigma-Aldrich 
(Missouri, USA), NA from Bayer Schering Pharma 
(Switzerland, Europe), and Pioglitazone from Amoun 
Pharmaceutical Industries Co., (Cairo, Egypt). Pure 
sample of acteoside was provided by the fourth author. 
Isolation of acteoside from J. mimosifolia leaves was 
carried out as previously reported by Moharram and 
Marzouk [5]. All other chemicals and reagents were of 
analytical grade.
Diabetes induction
After 12 h fasting, diabetes was induced in rats 
by a single intraperitoneal dose of STZ (52.5 mg/kg) 
dissolved in 0.1mol/L citrate buffer (pH 4.5) [15]. STZ 
was given 15 min after intraperitoneal injection of NA 
(25 mg/kg) [16]. The next 24 h following STZ injection, a 
5% glucose solution was given to rats to overcome the 
risk of death that may result from hypoglycemic shock. 
After 48 h of STZ injection, blood glucose levels were 
estimated in blood samples withdrawn from the tail vein 
using a portable glucometer. Rats were considered 
diabetic only if fasting blood glucose was ≥250 mg/dL.
Experimental design
After weighing rats, they were randomly 
distributed into six groups (six rats per group): Group I: 
Served as the normal control (given only distilled water); 
Group II: Diabetic control group; Groups III-V: Diabetic 
rats treated with oral acteoside for 3 weeks (10, 20, and 
40 mg/kg), respectively; and Group IV: Diabetic rats 
treated with oral pioglitazone (30 mg/kg) for 3 weeks. 
The vehicle was given to normal and diabetic control 
rats. Acteoside or pioglitazone treatments were started 
after confirmation of hyperglycemia, 48 h following STZ 
injection.
Acteoside and pioglitazone doses were 
selected according to the previously published data by 
Liu et al. [17] and by Vidal et al. [18], respectively.
Body weight changes
Initial body weight was determined by weighing 
each rat before the beginning of the experiment. 
Furthermore, the final body weight for each rat was 
estimated 24 h after the last dose of administration of 
either vehicle or treatment according to the study design. 
The percent change in body weight was calculated as 
follow:
% Change in body weight = (Final body 
weight-initial body weight/Initial body weight) × 100
Biochemical analysis
Glucose level
Glucose level (mg/dl) was measured 
colorimetrically using kits purchased from (Biodiagnostic, 
Egypt) based on the method by Trinder [19].
Serum insulin level
Serum insulin level (µIU/ml) was measured 
by enzyme-linked immunosorbent kit Rat Insulin (INS) 
ELISA (Cusabio Biotech Co., Ltd., Hubei, China) 
following the manufacturer’s protocol.
Glycosylated hemoglobin level (HbA1c)
Glycosylated Hb level (ng/ml) was estimated 
using (Rat [HbA1c] ELISA) purchased from Glory 
Science, following the manufacturer’s protocol.
Serum triglyceride and total cholesterol levels
Triglycerides level (mg/dl) and total cholesterol 
level (mg/dl) were determined using enzymatic methods. 
Diagnostic kits from Biodiagnostic, Egypt, were used 
following the method of Fossati and Prencipe [20].
Preparation of tissue homogenate
All rats were sacrificed by decapitation under 
anesthesia, and then their livers were removed. A 
portion from the liver was homogenized in (20% w/v) 
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ice cold 0.1 M phosphate buffer (pH 7.4). Then, the 
homogenate was centrifuged at 4000 rpm for 5 min in 
a cooling centrifuge (2k15; Sigma/Laborzentrifugen). 
The supernatant was then used for determining the 
liver contents of malondialdehyde (MDA) and reduced 
glutathione (GSH).
Hepatic lipid peroxide content
Hepatic MDA content (nanomoles/gram of liver 
tissue) was determined colorimetrically, as described 
by Satoh [21] using a diagnostic kit purchased from 
BioDiagnostic Co., Egypt.
Hepatic GSH content
Hepatic reduced GSH content (mmol/g 
liver tissue) was estimated by a colorimetric method 
according to Beutler et al. [22] using a kit purchased 
from BioDiagnostic Co., Egypt.
Evaluation of the antioxidant effect 
(in vitro)
1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical 
scavenging activity was determined following the 
method described by Peiwu et al. [23]. If the compound 
is antioxidant that can donate hydrogen, it will react 
with DPPH. The reaction will induce color change 
of DPPH from deep violet to yellow. This change in 
color was measured using a spectrophotometer at 
517 nm. Ascorbic acid at 0.1 M concentration was the 
standard [24]. DPPH radical scavenging activity was 
calculated according to the equation:
 Radical scavenging activity % = (Ac−At)/
Ac×100 (1)
Where Ac and At are the absorbance of control 
(DPPH) and acteoside, respectively.
Histopathological examination
Liver tissues were taken from rats and fixed in 
10% formaldehyde for 24 h. Then tissues were processed 
to obtain 4 µm paraffin embedded sections. The tissue 
sections were stained by hematoxylin and eosin stain 
and examined using the light microscope [25].
Statistical analysis
Results are expressed as mean ± SEM for six 
rats per group. Comparisons between more than two 
groups were carried out using one-way ANOVA followed 
by Tukey’s multiple comparisons test. All analyses were 
done using GraphPad Prism 6.0 statistical package 
for Windows (GraphPad, San Diego, Calif.). Statistical 
significance was set at p < 0.05.
Results
Effect of acteoside on body weight
Figure 1 reveals that diabetes induced by a 
single i.p. dose of STZ (52.5 mg/kg) 15 min after the 
i.p. injection of NA (25 mg/kg) led to a significant body 
weight loss of percentage of body weight by 11.86 ± 
1.32 after 3 weeks of diabetes induction. Meanwhile, 
normal rats showed a significant gain in % body weight 
by 22.74 ± 1.85. Acteoside given orally to diabetic rats 
in doses of 10, 20, and 40 mg/kg for 21 successive 
days resulted in significant gain in percentage of body 
weight by 19.05 ± 1.14, 16.92 ± 1.00, and 22.98 ± 1.21, 
respectively. Similarly, pioglitazone orally administered 
at 30 mg/kg showed a significant gain in percentage of 
body weight by 25.59 ± 2.13.
Figure 1: Effect of acteoside on body weight changes in diabetic rats. 
Results are expressed as % change of body weight (n = 6). Statistical 
analyses were carried out using one-way ANOVA followed by Tukey’s 
multiple comparison test. *Significant difference from normal group 
at p < 0.05. @Significant difference from control diabetic group at 
p < 0.05
Effect of acteoside on blood glucose, 
insulin levels, and HbA1c
As demonstrated in Table 1, diabetic rats 
showed a significant elevation in blood glucose to a level 
of 318.70 ± 13.8 mg/dl whereas normal rats mean level 
was 81.51 ± 4.15 mg/dl. Three weeks oral treatment with 
acteoside (10, 20, and 40 mg/kg) caused a significant 
reduction of blood glucose to 111.30 ± 0.61, 74.88 ± 
3.23, and 75.15 ± 8.45 mg/dl, respectively, versus 
control value. Furthermore, pioglitazone (30 mg/kg) 
reduced blood glucose level to 103.00 ± 3.12 mg/dl 
versus control value of diabetic rats.
Regarding serum insulin levels, control diabetic 
rats showed a significantly decreased serum insulin 
level of 1.25 ± 0.07 µIU/ml whereas normal rats 5.32 ± 
0.27 µIU/ml. Oral treatment with acteoside (10 mg/kg) 
resulted in significant elevation in serum insulin level to 
be 3.23 ± 0.06 µIU/ml versus control diabetic and normal 
groups. Acteoside in dose of 20 mg/kg restored serum 
insulin level to be 5.38 ± 0.21 µIU/ml versus control 
value of diabetic rats. Oral treatment with acteoside 40 
mg/kg significantly increased serum insulin level to be 
6.80 ± 0.20 µIU/ml versus control diabetic and normal 
values. Pioglitazone treatment resulted in significant 
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increase in serum insulin level to be 8.00 ± 0.16 µIU/ml 
versus control diabetic and normal values (Table 1).
As depicted in Table 1, control diabetic rats 
had significantly elevated HbA1c level of 40.30 ± 
3.39 ng/ml as compared to mean normal values of 3.36 
± 0.21 ng/ml. Acteoside in doses of 10 and 20 mg/kg 
showed a significant elevation in HbA1c levels to be 
24.12 ± 1.88 ng/ml and 16.72 ± 1.06 ng/ml, respectively, 
versus values of control diabetic rats and normal rats. 
Acteoside (40 mg/kg) significantly reduced HbA1c level 
to be 10.18 ± 0.92 ng/ml versus control diabetic rats. 
Similarly, pioglitazone significantly reduced HbA1c level 
to be 6.42 ± 0.29 ng/ml versus values of control diabetic 
rats.
Effect of acteoside on total cholesterol and 
triglyceride levels
The effect of acteoside on total cholesterol and 
triglyceride is shown in Table 2. Control diabetic rats 
showed a significant increase in total cholesterol to be 
139.35 ± 4.28 mg/dl as compared to normal values 94.38 
± 2.38 mg/dl. Oral treatment with acteoside (10, 20, and 
40 mg/kg) significantly reduced total cholesterol level to 
be 96.24 ± 1.08, 90.62 ± 1.60, and 95.14 ± 4.65 mg/dl, 
respectively, versus control diabetic rats’ values. In the 
same manner, pioglitazone (30 mg/kg) restored total 
cholesterol level to be 96.80 ± 4.17 mg/dl versus control 
value of diabetic rats. Concerning triglyceride levels, 
control diabetic rats showed a significant elevation in 
triglycerides level to be 153.90 ± 3.33 mg/dl as compared 
to normal values 107.80 ± 2.00 mg/dl. Oral treatment 
with acteoside (10, 20, and 40 mg/kg) restored total 
cholesterol level to be 118.59 ± 6.46, 100.27 ± 4.19, 
and 91.89 ± 3.20 mg/dl versus control value of diabetic 
rats. Furthermore, pioglitazone restored triglyceride 
level to be 108.98 ± 9.14 mg/dl versus control diabetic 
rats’ value.
Effect of acteoside on MDA and GSH in 
liver
Results depicted in Figure 2a show that control 
diabetic rats significantly elevated hepatic MDA content 
to be 65.27 ± 2.63 nmol/g as compared to normal rats 
38.94 ± 1.57 nmol/g. Oral treatment with acteoside 
(10, 20, and 40 mg/kg) restored hepatic MDA contents 
to be 32.63 ± 2.14, 36.14 ± 2.75, and 39.40 ± 1.14 
nmol/g, respectively, versus control diabetic rats’ value. 
Similarly, pioglitazone (30 mg/kg) restored hepatic 
MDA content to be 39.30 ± 3.49 nmol/g versus control 
diabetic rats’ value.
Regarding hepatic GSH content, control 
diabetic rats significantly reduced hepatic GSH content 
to be 6.61 ± 0.17 mmol/g whereas normal values 
8.69 ± 0.16 mmol/g. Acteoside (10, 20, and 40 mg/kg) 
significantly increased hepatic GSH contents to be 8.99 
± 0.37, 8.30 ± 0.21, and 8.56 ± 0.39 mmol/g versus 
control diabetic rats’ value. Furthermore, oral treatment 
with pioglitazone (30 mg/kg) restored hepatic GSH to 
be 9.00 ± 0.30 mmol/g versus control diabetic rats’ 
value (Figure 2b).
In vitro antioxidant activity of acteoside
In vitro antioxidant activity of acteoside versus 
ascorbic acid (0.1 M concentration), using DPPH radical 
scavenging activity method is depicted in Figure 3. 
After reaction time of 5 min, different concentrations 
of acteoside (200, 150, 100, and 50 mg/ml) showed a 
maximum reactive reaction rates of 74.4, 74, 73, and 
72.3%, respectively. In the same manner, the reactive 
reaction rate of L-ascorbic acid was 82.5%.
Effect of acteoside on histopathologic 
examination of the liver
In normal rats, no histopathologic alterations 
were found. Normal histological structure of the central 
vein and surrounding hepatocytes in the parenchyma 
was recorded in the normal group (Figure 4a). 
Pathological changes that recorded in the liver of control 
diabetic rats were severe dilatation and congestion of 
the central and portal vein associated with collagen 
proliferation and few inflammatory cells infiltration in 
the periductal tissue surrounding the hyperplastic bile 
ducts in the portal area (Figure 4b and c). Apoptosis 
was detected in few hepatocytes associated with 
diffuse kupffer cells proliferation (Figure 4d). Rats 
that were orally treated with acteoside (10, 20, and 
40 mg/kg), respectively, showing marked reduction 
of the previously mentioned histopathological lesions 
(Figures 4e, f and 5a-d) that were observed in control 
diabetic group (Group II). Pioglitazone treated diabetic 
group (Group IV) showed few inflammatory cells 
infiltration in the portal area (Figure 5e). Furthermore, 
there was a diffuse kupffer cells proliferation in between 
the hepatocytes (Figure 5f).
Table 1: Effect of acteoside on blood glucose, serum insulin, and glycosylated hemoglobin in diabetic rats
Treatment Parameters
Blood glucose (mg/dl) Serum insulin (µIU/ml) GHbA1c (ng/ml)
Normal 81.51@±4.15 5.32@±0.27 3.36@±0.21
Control diabetic (STZ+Nicotinamide) 318.7*±13.8 1.25*±0.07 40.30*±3.39
Diabetic+Acteoside (10 mg/kg) 111.3@±0.61 3.23*@±0.06 24.12*@±1.88
Diabetic+Acteoside (20 mg/kg) 74.88@±3.23 5.38@±0.21 16.72*@±1.06
Diabetic+Acteoside (40 mg/kg) 75.15@±8.45 6.80*@±0.20 10.18@±0.92
Diabetic+Pioglitazone (30 mg/kg) 103.0@±3.12 8.00*@±0.16 6.42@±0.29
Results are expressed as mean±SEM (n=6). Statistical analyses were carried out using one-way ANOVA, followed by Tukey’s multiple comparison test. *Significant difference from normal group at p<0.05. @Significant 
difference from control diabetic group at p<0.05.
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from many medicinal plants and is becoming of 
interest because of its wide range of pharmacological 
actions [27]. Acteoside utilized in this work was isolated 
from Jacaranda mimosifolia D. leaves grown in Egypt. 
Hereby, we explored the antidiabetic effect of acteoside 
in a rat model of diabetes induced by STZ-NA. This 
animal model of Type 2 diabetes is considered a well-
accepted experimental model that allows for preclinical 
examination of potential new antidiabetic agents [28]. 
In this work, pioglitazone was used for comparison. 
Pioglitazone belongs to the thiazolidinediones (TZDs) 
group of drugs which are used in the treatment of Type 
2 diabetes. TZDs act as insulin sensitizers through 
activation of peroxisome proliferator-activated receptor-
gamma (PPARγ) receptors. Activation of these nuclear 
receptors affects glucose and lipid metabolism [29].
Results of the current work demonstrated 
significant antidiabetic and antioxidant effects of 
acteoside that was comparable to that of pioglitazone. 
Acteoside or pioglitazone treatment for 3 weeks caused 
a significant decrease in serum glucose and HbA1c as 
compared to their levels in control diabetic rats. This 
was associated with beneficial effect on body weight 
in contrast to the weight loss demonstrated in diabetic 
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Figure 3: Antioxidant activity of acteoside and ascorbic acid (0.1 M 
concentration) in vitro, using 1,1-diphenyl-2-picrylhydrazyl radical 
scavenging activity method
Table 2: Effect of acteoside on total cholesterol and 
triglycerides in diabetic rats
Treatment Parameters
Total cholesterol (mg/dl) TG (mg/dl)
Normal 94.38@±2.38 107.8@±2.00
Control diabetic (STZ+Nicotinamide) 139.35*±4.28 153.90*±3.33
Diabetic+Acteoside (10 mg/kg) 96.24@±1.08 118.59@±6.46
Diabetic+Acteoside (20 mg/kg) 90.62@±1.60 100.27@±4.19
Diabetic+Acteoside (40 mg/kg) 95.14@±4.65 91.89@±3.20
Diabetic+Pioglitazone (30 mg/kg) 96.80@±4.17 108.98@±9.14
Results are expressed as mean±SEM (n=6). Statistical analyses were carried out using one-way ANOVA, 
followed by Tukey’s multiple comparison test. *Significant difference from normal group at p<0.05. 
@Significant difference from control diabetic group at p<0.05. TG: Triglyceride.
Discussion
Herbal medicines provide a valuable 
source of new antidiabetic therapies that could 
be safe and cost-effective [26]. Acteoside 
[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-
5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-
3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] 
(E)-3-(3,4-dihydroxyphenyl)prop-2-enoate) was isolated 
Figure 2: Effect of acteoside on (a) hepatic Malondialdehyde and 
(b) reduced glutathione contents in diabetic rats results is expressed 
as mean ± SEM (n = 6). Statistical analyses were carried out using 
one-way ANOVA followed by Tukey’s multiple comparison test. 
*Significant difference from normal group at p < 0.05, @Significant 
difference from control diabetic group at p < 0.05
a
b
Figure 4: Photomicrograph of liver in different groups. (a) Group 
I showing normal histological structure of the central vein and 
surrounding hepatocytes (H&E, ×40). (b) Group II showing severe 
dilatation and congestion of both central and portal veins with 
periductal collagen proliferation and few inflammatory cells infiltration 
surrounding the hyperplastic bile ducts in portal area (H&E ×40). 
(c) Higher magnification of the previous picture showing the congested 
dilated portal and central vein with collagenous proliferation and 
few inflammatory cells infiltration surrounding the hyperplastic bile 
duct in portal area. (d) Group II showing the apoptosis in some few 
hepatocytes with diffuse kupffer cells proliferation in between H&E, 
×80. (e) Group III showing dilatation of both central and portal vein 
with periductal collagen proliferation surrounding the bile duct at 
portal area (H&E, ×40). (f) Group III showing diffuse kupffer cells 
proliferation in between the hepatocytes (H&E, ×80)
a b
c d
e f
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untreated group. Pioglitazone restored the reductions 
in rats’ body weight caused by STZ-induced diabetes. 
This effect is reported by other studies and could be 
attributed to increase in insulin sensitivity which is a part 
of pioglitazone pharmacological actions [30]. However, 
in some reports, the drug was found to increase body 
weight due to increased appetite, lipogenesis, and fluid 
retention [31]. These different results in the literature 
could be related to the diabetes model used and the 
duration of the study. Improvement of body weight 
caused by acteoside could be related to its ability to 
reduce hyperglycemia. Other studies reported that 
acteoside reduces weight due to inhibition of pancreatic 
lipase [32] as well as improving levels of post prandial 
glucose in response to a load of starch in mice [14].
Our study demonstrated an antihyperglycemic 
effect of acteoside in STZ-NA-induced diabetes. 
Hyperglycemia increases the liability of proteins to 
glycation resulting in changes in their structure and 
function. Non-enzymatic gylcation of globin fraction 
of hemoglobin produces HbA1c which is used for 
reliable monitoring of glycemic control in diabetes [33]. 
In agreement with the previous reports using STZ-NA 
model of diabetes; in this investigation, HBA1c was 
higher in the diabetic model group compared to the 
control vehicle group [34], [35]. Treatment with either 
pioglitazone or acteoside improved glycemic control 
over the study period as indicated by blood glucose 
and HbA1c levels in the treated groups. Pioglitazone 
as a PPAR γ agonist improves fasting blood glucose 
and HA1c through increased insulin sensitivity 
in liver, muscle, and adipose tissue; effects were 
repeatedly reported both in experimental and in human 
diabetes [36], [37]. There was a comparable effect of 
acteoside on glycemic control in this study. This could 
be mediated through acteoside ability to scavenge free 
radicals produced by STZ with improvement of beta 
cell function and insulin levels or through improving 
target organ response to insulin. Acteoside successfully 
prevented in vitro production of advanced glycation 
end products (AGE) [12]. These products were found 
to induce resistance to insulin action in adipocytes, 
muscles, and hepatocytes [38]. In addition, high levels of 
AGE produced in chronic hyperglycemia bind to cellular 
membrane receptors to increase free radicals through 
activating NADPH oxidase [39]. Taking these studies 
into consideration, acteoside could have exerted its 
beneficial effect in diabetic rats, at least partly, through 
improving insulin resistance.
The findings of this study showed that 3 
weeks treatment with pioglitazone or acteoside exerted 
a significant amelioration of total cholesterol and 
triglyceride (TG) levels, hepatic lipid peroxidation, and 
GSH. Moreover, it prevented the histopathological 
changes in liver architecture associated with STZ-NA 
diabetes. Reactive oxygen species production is 
augmented in diabetes and prolonged oxidative burden 
play a part in the development of long-term diabetes-
related complications. Antidiabetic agents offering 
antioxidant action could be effective in preventing, 
or at least delaying, and progression of diabetes 
complications [40]. Pioglitazone antioxidant capacity is 
well documented in STZ models of diabetes and in various 
tissues including the liver [36], [41]. Structure-activity 
studies of acteoside revealed that the hydroxyphenyl 
ethyl and caffeoyl moieties of the compound are thought 
to be responsible for its antioxidant effects [27]. In the 
current experiment, to examine the antioxidant activity 
of acteoside in comparison to pioglitazone, hepatic 
MDA contents – an indicator of lipid peroxidation – and 
GSH liver contents were estimated. In addition, in vitro 
study using DPPH assay was employed to assess 
acteoside free radical scavenging activity. Acteoside 
showed antioxidant activity in vitro and was able to 
reduce MDA levels and restore GSH in livers of diabetic 
rats. Consistent with these results, previous studies 
reported the ability of acteoside to cause a significant 
reduction in lipid peroxidation and reversal of hepatic 
GSH depletion induced by carbon tetrachloride [8]. In 
a different study by Peerzada et al. [10], acteoside was 
able to protect rat liver cells against diethylnitrosamine-
induced carcinogenesis by preventing DNA damage and 
cell apoptosis. The effect was further elucidated through 
acteoside’s ability to scavenge reactive oxygen species 
produced by diethylnitrosamine. Furthermore, in a prior 
study, acteoside protected pulmonary endothelial cells 
against oxidative stress induced by hydroxyl radical. In 
this mentioned study, acteoside also demonstrated the 
Figure 5: Photomicrograph of liver in different groups. (a) Group IV 
showing inflammatory cells infiltration in the portal area (H&E, ×40). 
(b) Group IV showing diffuse kupffer cells infiltration proliferation in 
between the hepatocytes (H&E, ×80). (c) Group V showing dilatation 
of the portal vein (H&E, ×16). (d) Higher magnification of the previous 
picture showing the inflammatory cells infiltration in portal area 
(H&E, ×40). (e) Group VI showing few inflammatory cells infiltration 
in portal area (H&E, ×40). (f) Group VI showing diffuse kupffer cells 
proliferation in between hepatocytes (H&E, ×80)
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ability to scavenge DPPH radicals in a dose-dependent 
manner [42]. Studies investigating the antioxidant 
property of various phenylethanoids especially acteoside 
have demonstrated that these compounds protect cells 
due to their direct antioxidant and scavenging activity 
of free radicals. Other reports further explained the 
antioxidant effect of acteoside at subcellular levels. 
Acteoside upregulate the endogenous antioxidant-
defensive systems [43]. This effect of acteoside could 
be exerted at the level of post-transitional modification 
or at gene transcription of redox enzymes. In vitro and 
in vivo neuroprotective effects of acteoside was found 
to occur through activation of Nrf2, a transcription factor 
for genes encoding antioxidant and stress responsive 
proteins [9], [44].
Liver is one of the major organs affected by 
impaired insulin levels or action. In diabetes, there is 
activation of glycogenolysis leading to higher hepatic 
production of glucose. Furthermore, insulin resistance 
through changes in lipid metabolism and provision 
of inflammatory milieu contribute to the development 
of liver fatty changes. High levels of free fatty acids 
in insulin-resistance can exert direct toxic effect on 
hepatocytes and increase pro-inflammatory cytokines 
release contributing to hepatocellular changes seen 
in diabetes [45]. In our experiment, diabetic rats 
demonstrated higher levels of total cholesterol and 
triglycerides than the levels found in control non-
diabetic rats. After 3 weeks daily administration of 
acteoside or pioglitazone, the levels of total cholesterol 
and triglycerides were improved in the diabetic group 
compared to their counterpart levels in diabetic untreated 
rats. In addition, histopathological examination of livers 
from diabetic rats showed histopathological changes 
that were significantly ameliorated by treatment with 
either pioglitazone or acteoside. This pioglitazone 
effect is in line with the previous reports. Pioglitazone 
ameliorated increases in total cholesterol and TG in 
STZ-induced diabetes; an effect that was accompanied 
by upregulation of hepatic PPARγ [46]. Regarding 
the improvement in cholesterol and TG levels after 
treatment with acteoside it could be explained by its 
antidiabetic effect which was sustained throughout the 
study period as indicated by lower levels of HBA1c in 
treated rats. However, the literature provides evidence 
linking acteoside to PPAR-alpha (PPAR-α). PPAR-α 
is expressed in high amounts in liver, muscles, heart, 
and kidney, and acts chiefly to control genes concerned 
with lipids and lipoproteins metabolism. In the liver, 
this transcription factor control genes of proteins and 
enzymes regulating β-oxidation of fatty acids and lipid 
transport [47]. In a report by Esposito et al. [48], PPAR-α 
was linked to the anti-inflammatory effect of acteoside 
in experimental inflammatory bowel disease model of 
PPAR-α knock-out mice. Moreover, in a recent review 
of natural products with potential anti-dyslipidemic effect 
through targeting PPAR-α, acteoside was considered as 
one of these products [49]. However, more studies are 
needed to prove this mechanism of acteoside action.
Conclusion
The evidence from this study suggests that 
acteoside has antidiabetic and antioxidant effects. In 
addition, it offered advantages in the control of Type 2 
diabetes induced by STZ-NA in rats through ameliorating 
body weight changes, cholesterol, and TG levels. The 
antioxidant effects were evidenced by reducing lipid 
peroxidation, DDPH activity and elevating GSH content 
as well as ameliorating hepatic histopathological 
alterations of diabetes. However, more in depth 
experimental studies of the detailed mechanisms 
behind these beneficial effects are warranted.
Structure of acteoside
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